contact us rémun

Normandin Beaudry | A Leader in Total Rewards

Select your total rewards challengeWhat is your specific need?

Explore our areas of expertise

We create human capital and financial performance with our clients through the excellence of our experts ignited by a total rewards mindset.

Since 1992, we have been sharing our cutting-edge knowledge in all our areas of expertise. Normandin Beaudry sets itself apart as a firm that is committed to straight talk: we’re always there in black and white.


Normandin Beaudry is founded

Owned exclusively by its professionals

Count on the presence and stability of key employees

More than 250 employees

ignited by a total rewards mindset

A visionary leader

in total rewards and actuarial consulting

An enviable roster of Canadian clients

Major corporations, SMBs, para-governmental organizations, municipalities and non-profit organizations

8 areas of expertise

  • Health
  • Performance
  • Group Benefits
  • Investment Consulting
  • Compensation
  • Communication
  • Pension and Savings
  • Pension Plans Administration


Bill 132: amendments to the Pension Benefits Act of Ontario

On October 28, 2019, Bill 132 (An Act to reduce burdens on people and businesses by enacting, amending and repealing various Acts and revoking various Regulations) was introduced in the Legislative Assembly of Ontario.

Read more

Good News for Retirement Security — A new option will soon be available in Quebec

On November 7, the Quebec Minister of Finance presented his economic update on Quebec’s finances. The Minister, who is also responsible for Retraite Québec, had good news in this regard.

The Minister confirmed the Government of Quebec’s desire to offer a new pension plan option for Quebec employers and workers. In this respect, the government will propose a regulatory framework to introduce target benefit plans (TB plans).

Read more

Biosimilars: Further steps taken by British Columbia and Alberta

In September 2019, the Government of British Columbia added two major medical conditions to its rules concerning the switch to biosimilars. People who use Remicade to treat ulcerative colitis and Crohn’s disease will have to modify their prescription and switch to the biosimilar version of their medication by March 5, 2020. The use of original biologics will be allowed for exceptional medical reasons only.

Read more

Our coordinates


630 René-Lévesque Blvd West, 30th floor
Montreal, QC H3B 1S6



180 John Street
Toronto, ON M5T 1X5


Quebec City

1751 du Marais, Suite 300
Quebec City, QC G1M 0A2